Association between promoter polymorphisms of OPN gene and cancer risk: a meta-analysis.

Abstract

BackgroundResults of the association between polymorphisms of osteopontin (OPN) gene promoter region and risk of cancer were inconclusive. The aim of this meta-analysis was to elucidate whether OPN promoter polymorphisms were associated with cancer risk.MethodsElectronic databases including PubMed, Web of Science, and Chinese National Knowledge Infrastructure were systematically searched. Odd ratios (ORs) and their 95% confidential interval (CI) were used to assess the strength of association between OPN promoter polymorphisms and cancer risks.ResultsNine studies were finally included in this meta-analysis. For OPN rs17524488 polymorphism, carriers of GG or -/G genotype were significantly associated with increased cancer risk compared with wild-type -/- carriers, respectively (GG vs -/-: OR =1.40, 95% CI =1.03–1.91, P=0.033; -/G vs -/-: OR =1.22, 95% CI =1.07–1.40, P=0.002). Additionally, G allele was significantly associated with increased cancer risk compared with (-) allele (OR =1.21, 95% CI =1.04–1.40, P=0.016). However, no significant association was observed of OPN rs11730582 polymorphism and cancer risk (CC vs TT: OR =0.98, 95% CI =0.49–1.97, P=0.964; CT vs TT: OR =0.88, 95% CI =0.54–1.43, P=0.610).ConclusionCarriers of GG or -/G genotype of OPN promoter rs17524488 (-156-/G) polymorphism might be associated with increased risk of cancer compared with wild-type -/- carriers, respectively. However, no significant association was observed between OPN promoter rs11730582 (-443C/T) polymorphism and risk of cancer.